HCPCS code J9228 – Ipilimumab (Yervoy) injection, per 1 mg

Key takeaways

HCPCS code J9228 covers ipilimumab (Yervoy) and is billed per 1 mg, so a 225 mg dose is reported as 225 units.

Yervoy is FDA-approved for melanoma and, with nivolumab, for kidney, colorectal, liver, lung, pleural mesothelioma and esophageal cancers.

Doses are weight-based at 1 mg/kg or 3 mg/kg depending on the indication, so the unit count changes with every patient.

Yervoy ships in 50 mg and 200 mg single-dose vials, so Medicare claims carry JW for discarded drug or JZ when none is discarded.

Pabau, the practice management platform we build, keeps the dose, vial NDC and claim details together in one patient record.

HCPCS Code J9228: Definition and official descriptor

HCPCS Code J9228 is the CMS code for “injection, ipilimumab, 1 mg.”

It sits in the J-series of HCPCS Level II codes, which covers drugs administered other than by mouth. The code identifies Yervoy, the ipilimumab product made by Bristol Myers Squibb. CMS made J9228 effective on January 1, 2012, replacing the temporary hospital outpatient code C9284.

The key number in the descriptor is 1. Each billing unit equals 1 mg of ipilimumab, so the units on the claim match the milligrams infused. Billers who reach for a multiplier, as some 0.1 mg or 10 mg drug codes require, overbill or underbill the claim.

Drug overview: Ipilimumab (Yervoy)

Ipilimumab is a monoclonal antibody that blocks CTLA-4, a receptor that acts as a brake on T-cell activity. By stopping CTLA-4 from binding its ligands, CD80 and CD86, the drug lets T cells activate and multiply against the tumor.

The FDA first approved Yervoy in 2011 for advanced melanoma. Its label has since grown to eight indications, and most of them pair ipilimumab with nivolumab (Opdivo). Because the drug acts on the immune system, its main risks are immune-mediated reactions in the gut, liver, skin, glands and lungs.

• Mechanism: CTLA-4 blockade, which increases T-cell activation, including tumor-infiltrating T cells.
• Strengths: 50 mg/10 mL and 200 mg/40 mL single-dose vials, both at 5 mg/mL. The label says to discard partially used vials.
• Administration: Diluted and given as a 30-minute IV infusion through a low-protein-binding in-line filter. When given with nivolumab, nivolumab goes first on the same day.
• Dose basis: Milligrams per kilogram of body weight, at 1 mg/kg or 3 mg/kg depending on the indication.

FDA-approved indications and ICD-10 diagnosis codes

A diagnosis code that doesn’t match an FDA-approved or compendia-supported use is the quickest route to a J9228 denial. The table below maps each indication on the current Yervoy label to its main ICD-10-CM category.

The lung cancer and colorectal indications also depend on biomarker results from an FDA-authorized test. Keep the PD-L1, MSI-H or dMMR report in the record, because payers ask for it at prior authorization and in audits. Check the indications against the current Yervoy prescribing information, which was last revised in August 2026.

How to bill HCPCS Code J9228: Unit calculation and dose reporting

J9228 is billed per 1 mg of ipilimumab administered. To find the units, multiply the prescribed dose in mg/kg by the patient’s weight in kilograms. The milligram total is the unit count.

The worked examples below show how dose, vial choice and discarded drug land on the claim. Patient weights are illustrative.

Drawn to scale, the same four cases show how much of each opened vial ends up on a JW line.

1. Record the dose administered from the infusion record, not only the order. Weight changes between cycles change the dose.
2. Report one unit per milligram. A 225 mg dose is 225 units of J9228.
3. Add JW or JZ. Medicare has required one of these on single-dose container drugs since July 1, 2023. Bill discarded milligrams on a second J9228 line with JW. Use JZ on the line when no drug is discarded.
4. Report the NDC where the payer requires it: 00003-2327-11 for the 50 mg vial or 00003-2328-22 for the 200 mg vial, in 11-digit format.
5. Bill the infusion separately. J9228 covers the drug only. The infusion is usually reported with CPT 96413, or 96417 when it follows a same-day nivolumab infusion.

Medicare coverage and reimbursement for J9228

Medicare Part B pays J9228 at the Average Sales Price (ASP) plus 6% in the physician office. CMS updates ASP payment limits every quarter, so a rate from last quarter may already be out of date.

Pull the current figure from the CMS ASP pricing files before quoting a patient or checking a remittance. Multiply the per-unit limit by the units billed, because J9228 pays per milligram.

Medicare covers anticancer drugs for their FDA-labeled uses. It also covers off-label uses supported by recognized compendia, under the Medicare Benefit Policy Manual, chapter 15, section 50.4.5. Document the compendia citation in the record for any off-label claim.

Prior authorization and medical necessity requirements

Traditional Medicare doesn’t require prior authorization (PA) for J9228, but many Medicare Advantage and commercial plans do. Check each plan before the first infusion. Some plans also authorize a set number of doses, so a new request may be needed for maintenance cycles.

Where a payer requires PA, the request typically includes:

• A confirmed diagnosis that matches a labeled or compendia-supported indication, with pathology.
• Biomarker results where the indication depends on them, such as PD-L1, MSI-H or dMMR status.
• The planned regimen, including the nivolumab partner, the mg/kg dose and the number of doses.
• The patient’s current weight and performance status.
• Prior therapy, where the indication requires it, such as sorafenib before second-line liver cancer treatment.

Match the request to the wording of the payer’s own Yervoy policy, rather than sending generic office notes. Payer policies list the exact criteria, dose limits and authorization periods they apply.

Documentation requirements for J9228 claims

A J9228 claim that survives a MAC or RAC audit needs a record that supports the diagnosis, the dose and the waste. Keeping medical billing compliance records consistent across every cycle protects the practice in post-payment review.

• Signed order: Drug name, dose in mg/kg, calculated milligrams, cycle number and the nivolumab partner where one is given.
• Weight on the day of treatment: The dose is weight-based, so the record must show the weight used.
• Diagnosis and biomarker evidence: Pathology, staging and any PD-L1, MSI-H or dMMR test the indication depends on.
• Infusion record: Start and stop times, the volume infused and any reaction or interruption.
• Vial and waste record: Vial sizes and NDCs opened, lot numbers, milligrams given and milligrams discarded.
• Immune-related monitoring: Liver enzymes, creatinine and thyroid function at baseline and before each dose, as the label advises.

Capturing these fields on a structured superbill at the time of service is easier to defend than addenda written after a denial.

Codes confused with HCPCS Code J9228

Ipilimumab is often given on the same day as other checkpoint inhibitors, so its code sits next to theirs on the claim. Each drug has its own code and billing unit.

Using J3490 or J9999 for Yervoy sends the claim to manual pricing and delays payment. If a payer rejects J9228, call provider relations before switching codes, because the cause is usually a modifier, unit or NDC error.

Common claim denial reasons for J9228 and how to avoid them

Most J9228 denials trace back to a handful of root causes, and each one has a workflow fix. Handling denial management at the code level costs less than fixing the same error at appeal every cycle.

A clean claim for J9228 gets each of these elements right on the first submission. Yervoy runs on fixed 3-week or 6-week cycles, so an uncorrected error repeats with every infusion.

How Pabau keeps J9228 claims consistent from infusion to payment

Most J9228 errors start at the chair. The weight sits in the visit note, the vial NDC on the label and the waste in a nurse’s log. A biller then rebuilds the claim from all three by hand.

Pabau keeps the treatment note, dose and stock records in the same patient record. Its claims software for oncologists builds the claim from that record. The milligrams given, the waste and the vial details logged at the infusion carry through to the claim lines.

Pabau’s scheduling handles the cycle. Booking each Yervoy infusion 3 or 6 weeks out, with an automated reminder, keeps the regimen on the dates the authorization covers.

Track Yervoy billing from dose to claim

Pabau records the dose, vial NDC and discarded milligrams at the point of care. J9228 claims go out with the right units and modifiers, and the audit trail is already complete.

Book a demo

Conclusion

J9228 is simple on paper, because one unit equals one milligram. The claims that fail are the ones where waste, vial mix and NDC are rebuilt by hand after the infusion.

Set the vial logic and the JW or JZ rule once in your charge capture, and tie every claim to a labeled indication. Then each 3-week or 6-week cycle bills the same way.

To see how Pabau keeps Yervoy doses, vial records and claim lines in step, book a demo.

Continue your research

Want to understand how electronic remittance advice connects to denial resolution? Electronic remittance advice guide explains how to read CARC and RARC codes from the ERA to identify the correct corrective action.

Exploring how the 837P format carries NDC data? 837 file billing guide covers loop 2410 NDC reporting and how electronic claims transmit drug information to payers.

Billing the nivolumab dose on the same claim? HCPCS code J9299 covers Opdivo units, NDC reporting and how it pairs with Yervoy.

Coding the infusion that delivers the drug? CPT code 96413 explains the first-hour chemotherapy infusion code billed alongside J9228.

Frequently asked questions